Warhound's $200 million plan for genetically enhanced military dogs

By Rebecca Stone

Warhound has secured $200 million in investor funding for a plan to gene-edit military and police dogs and equip them with Anduril technology, but the startup has not yet produced the animals it hopes to deploy.

The Texas-based defense startup is the brainchild of Palmer Luckey of Anduril and Ben Lamm, co-founder of Colossal Biosciences, which says it is trying to resurrect extinct animals. Bloomberg reports that Luckey helped conceive Warhound but holds no equity and has no ongoing role.

Luckey distilled the proposition in the launch announcement: “Man’s best friend deserves man’s best tech.” Warhound’s plan pairs animal genetics with Anduril’s cybernetic equipment, but the partnership remains a development program rather than a deployed system.

The $200 million total comes from investors, but Warhound has not disclosed how much will fund breeding, equipment integration or certification. The proposal also links two organizations with different core businesses: Colossal would supply the biological work, while Anduril would supply the military hardware.

What hardware would the dogs carry?

Warhound plans to use Colossal’s work in genetics, cloning and animal biology to produce healthier dogs with characteristics suited to demanding missions. Anduril would then equip them with what the announcement calls its “advanced cybernetic Augments”: eye and ear protection plus EagleEye military technology.

Warhound says the package would give animals and handlers “greater awareness and protection in the field.” That remains a design goal: none of the genetically modified dogs exists yet.

Gene editing would target health and performance, while the Augments would add protection and awareness; neither layer replaces the need for animal training or certification of Warhound’s training programs. The announcement does not describe how the hardware will fit working breeds or whether the eye and ear protection must be adapted for individual animals.

Where would the dogs work?

If the program produces animals that can complete training, Warhound targets elite working roles in three areas:

• U.S. military forces
• Emergency first-response teams
• Law enforcement

Those are deployment targets, not current assignments. Warhound has not disclosed a production volume or timeline for the animals, and its announcement offers no benchmark for how quickly edited dogs could replace imported ones.

Why does the current supply chain matter?

Warhound’s press release says 80% of U.S. military dogs currently come from Europe. That concentration defines the supply-chain problem the startup wants to solve: produce suitable animals in the United States and improve the rate at which dogs qualify for specialist work.

According to the same release, less than half of dogs procured overseas typically are deemed fit for service after the current three-year acquisition-and-training pipeline. These are Warhound’s operating baselines, not independent forecasts or performance data from its own animals.

The startup links its two goals closely. Animals bred for health and performance would still need to qualify through training before they could reduce reliance on the overseas supply, making successful deployment dependent on biology, equipment and working-dog preparation moving together.

How would the genetics change the dogs?

In a statement to TechCrunch, Lamm said Colossal is looking to edit dogs’ genes to remove problems such as poor eyesight and cancer likelihood. The company also aims to add genes for performance “for things like speed and agility” or to enhance olfactory sensors for bomb sniffing “and whatnot.”

Those capabilities are proposed traits, not achieved characteristics in a Warhound animal. Belgian Malinois and German Shepherd, both high-performance working breeds, form the study base. Warhound says the aim is to create “a new type of dog.”

Although Colossal’s cloning and broader animal-biology work sits underneath the proposal, Warhound has not specified a cloning method, generation count or release schedule. The genetic program therefore remains a roadmap without disclosed production capacity.

Who will run and certify the program?

The American Humane Society will guide the company and certify its training programs. Marine veteran and intelligence specialist David Spirk has been named Warhound’s CEO. Spirk said the goal is simple: “healthier dogs, better-prepared teams, and more service members and first responders coming home safely.”

For Warhound, the next competitive test is whether it can convert the $200 million into a repeatable breeding, equipment-integration and certification effort that raises fitness above the less-than-half rate of the existing three-year overseas pipeline. No Warhound-modified dog, output target, price or delivery date has been disclosed, so capacity remains the central uncertainty.